share_log

Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

Benzinga ·  Sep 26 08:41

For the year six month period ended June 30

Note2024
unaudited
£'000
2023
unaudited
£'000
Revenue -298
Research and development costs (2,189)(2,251)
Administrative costs (2,034)(2,291)
Loss from operations (4,223)(4,244)
Finance income3839410
Finance expense3(49)(22)
Loss before tax (3,433)(3,856)
Taxation4125288
Loss for the period attributable to the owners of the parent (3,308)(3,568)
Total comprehensive loss attributable to the owners of the parent (3,308)(3,568)
Loss per share
Basic and diluted loss per ordinary share – pence5(0.1p)(3.6)p
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment